These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 26427613)
1. Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment. Santos PC; Pereira AC Pharmacogenomics; 2015; 16(15):1743-50. PubMed ID: 26427613 [TBL] [Abstract][Full Text] [Related]
2. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129 [TBL] [Abstract][Full Text] [Related]
4. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114 [TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia. López G; Bernal LM; Gelvez N; Gómez LF; Nova A; Sánchez AI; Tamayo ML Atherosclerosis; 2018 Oct; 277():434-439. PubMed ID: 30270082 [TBL] [Abstract][Full Text] [Related]
6. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work. Marbach JA; McKeon JL; Ross JL; Duffy D Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514 [TBL] [Abstract][Full Text] [Related]
7. A Chinese homozygote of familial hypercholesterolemia: identification of a novel C263R mutation in the LDL receptor gene. Wang D; Wu B; Li Y; Heng W; Zhong H; Mu Y; Wang J J Hum Genet; 2001; 46(3):152-4. PubMed ID: 11310584 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vuorio A; Tikkanen MJ; Kovanen PT Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. Alonso R; Andres E; Mata N; Fuentes-Jiménez F; Badimón L; López-Miranda J; Padró T; Muñiz O; Díaz-Díaz JL; Mauri M; Ordovás JM; Mata P; J Am Coll Cardiol; 2014 May; 63(19):1982-9. PubMed ID: 24632281 [TBL] [Abstract][Full Text] [Related]
10. Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. Wang J; Huff E; Janecka L; Hegele RA Hum Mutat; 2001 Oct; 18(4):359. PubMed ID: 11668627 [TBL] [Abstract][Full Text] [Related]
11. [Identification of a novel mutation at the point of low density lipoprotein receptor gene from a subject with familial hypercholesterolemia]. Liu YR; Tao QM; Chen JZ; Tao M; Guo XG; Shang YP; Zhu JH; Zhang FR; Zheng LR; Wang XX Sheng Li Xue Bao; 2004 Oct; 56(5):566-72. PubMed ID: 15497035 [TBL] [Abstract][Full Text] [Related]
12. Familial Hypercholesterolemia in Greek children and their families: genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum. Mollaki V; Progias P; Drogari E Atherosclerosis; 2014 Dec; 237(2):798-804. PubMed ID: 25463123 [TBL] [Abstract][Full Text] [Related]
13. Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred. Takada D; Emi M; Ezura Y; Nobe Y; Kawamura K; Iino Y; Katayama Y; Xin Y; Wu LL; Larringa-Shum S; Stephenson SH; Hunt SC; Hopkins PN J Hum Genet; 2002; 47(12):656-64. PubMed ID: 12522687 [TBL] [Abstract][Full Text] [Related]
14. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Jensen HK Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167 [TBL] [Abstract][Full Text] [Related]
15. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Ito MK; Watts GF Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207 [TBL] [Abstract][Full Text] [Related]
16. The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations. Tichý L; Freiberger T; Zapletalová P; Soška V; Ravčuková B; Fajkusová L Atherosclerosis; 2012 Aug; 223(2):401-8. PubMed ID: 22698793 [TBL] [Abstract][Full Text] [Related]
17. [Prevention of coronary heart disease in familial hypercholesterolemia]. Miserez AR; Keller U Ther Umsch; 1994 Oct; 51(10):671-6. PubMed ID: 7839323 [TBL] [Abstract][Full Text] [Related]
18. A combined LDL receptor/LDL receptor adaptor protein 1 mutation as the cause for severe familial hypercholesterolemia. Soufi M; Rust S; Walter M; Schaefer JR Gene; 2013 May; 521(1):200-3. PubMed ID: 23510778 [TBL] [Abstract][Full Text] [Related]
19. Functional characterization and classification of frequent low-density lipoprotein receptor variants. Etxebarria A; Benito-Vicente A; Palacios L; Stef M; Cenarro A; Civeira F; Ostolaza H; Martin C Hum Mutat; 2015 Jan; 36(1):129-41. PubMed ID: 25378237 [TBL] [Abstract][Full Text] [Related]
20. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]